- £1.54bn
- £1.51bn
- $1.19bn
Indivior PLC Morgan Stanley - Holding(s) in Company
Brief: Indivior Gets FDA Approval Of Sublocade Label Changes
FDA Approval of SUBLOCADE Label Changes
UK's Indivior shares tumble on lower 2025 revenue forecast (updated)
Indivior tumbles on falling sales forecast
UK's Indivior forecasts 17% decline in 2025 revenue
Brief: Indivior Outlook 2025 Adjusted Operating Profit $185m To $225m
Final Results
London-listed Indivior shares rise; FDA confirms no outstanding issues for Sublocade
Brief: Indivior Says FDA Delays Final Review Of Sublocade Label Changes
Notice of Results
Appointment of Independent Non-Executive Director
Brief: Indivior Appoints David Wheadon As Chair Of The Board
Dr. David Wheadon appointed Chair of the Board
Indivior PLC Morgan Stanley - Holding(s) in Company
Indivior PLC Morgan Stanley - Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Director/PDMR Shareholding